Table 2.
The combinations between DPP-4 inhibitors and other oral glucose-lowering agents authorized by the European Medicines Agency (EMA)
| Indications | Sitagliptin | Sita + Met | Vildagliptin | Vilda + Met | Saxagliptin | Saxa + Met | Linagliptin | Lina + Met |
|---|---|---|---|---|---|---|---|---|
| Alone | Yes | Yes | Yes | Yes | – | Yes | Yes | Yes |
| + Met | Yes | – | Yes | – | Yes | – | Yes | – |
| + TZD | Yes | Yes | Yes | – | Yes | – | – | – |
| + SU | Yes | Yes | Yes | Yes | Yes | – | – | Yes |
| + Met and SU | Yes | – | Yes | – | – | – | Yes | – |
| + Met and TZD | Yes | – | – | – | – | – | – | – |
| + Insulin and ± Met | Yes | Yes | Yes | Yes | Yes | Yes | – | – |
| Previous gliptin + Met (separately) | – | Yes | – | Yes | – | Yes | – | Yes |
| Dose adjustment in kidney impairment | Yes | Yes | Yes | Yes | Yes | – | – | – |
Abbreviations: DPP, dipeptidyl peptidase; Lina, linagliptin; Met, metformin; Saxa, saxagliptin; Sita, sitagliptin; Vilda, vildagliptin; SU, sulfonylurea; TZD, thiazolidinedione.